Glicorest

Glicorest is an oral medication that combines metformin hydrochloride and glibenclamide in one tablet. It belongs to the biguanide and sulfonylurea drug classes and is marketed in the European Union as a prescription product for managing blood glucose in adults with type 2 diabetes mellitus. The formulation is taken regularly by mouth and should be used under the supervision of a healthcare professional.

Glicorest is indicated for the treatment of type 2 diabetes mellitus in adults when diet, exercise, and monotherapy are insufficient to achieve target glycemic levels.

- Improves fasting plasma glucose by reducing hepatic glucose output (metformin component). - Lowers post‑prandial glucose through enhanced insulin secretion (glibenclamide component). - Can be used as part of a combination regimen with other oral antidiabetic agents. - May be considered when a single‑pill regimen is preferred to simplify therapy. - Supports overall HbA1c reduction when taken as prescribed.

The safety profile of Glicorest reflects the known effects of its two active ingredients, metformin and glibenclamide.

Common: - Gastrointestinal upset such as nausea, abdominal discomfort, or diarrhea. - Mild hypoglycemia, especially when meals are skipped or delayed. - Headache or dizziness. - Metallic taste in the mouth.

Serious: - Lactic acidosis, a rare metabolic emergency associated with metformin. - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions including skin rash, itching, or swelling. - Hepatotoxicity or significant elevation of liver enzymes.

Before initiating Glicorest, clinicians should evaluate patient-specific factors and monitor for conditions that may increase risk.

- Assess renal function; metformin is contraindicated in severe renal impairment. - Review hepatic status, as liver disease may predispose to lactic acidosis. - Use caution in elderly patients who are more susceptible to hypoglycemia. - Avoid use during acute or chronic metabolic acidosis. - Monitor for signs of heart failure, which can affect drug clearance. - Evaluate pregnancy or lactation status; safety data are limited.

Glicorest may interact with several medications; understanding these interactions helps minimize adverse outcomes.

Avoid: - Concurrent use of other sulfonylureas or meglitinides, which can cause additive hypoglycemia. - Strong inhibitors of renal tubular secretion of metformin (e.g., cimetidine) that raise metformin levels. - Iodinated contrast agents without appropriate hydration and monitoring.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Diuretics, especially thiazides, that can affect glucose control. - Corticosteroids, which may increase blood glucose and require dose adjustments. - Alcohol intake, which can potentiate metformin‑related lactic acidosis.